NCT02537743

Brief Summary

Evaluation of patient reported outcomes ( PRO) regarding typical ailments in the REAL LIFE Renal Cell Carcinoma population

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
98

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Aug 2015

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 19, 2015

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

August 26, 2015

Completed
7 days until next milestone

First Posted

Study publicly available on registry

September 2, 2015

Completed
5.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 19, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 19, 2021

Completed
Last Updated

March 25, 2021

Status Verified

March 1, 2021

Enrollment Period

5.5 years

First QC Date

August 26, 2015

Last Update Submit

March 24, 2021

Conditions

Renal Cell Carcinoma

Keywords

Patient Reported Outcomes

Outcome Measures

Primary Outcomes (1)

  • Primary Outcome Measure (Patient Reported Outcomes (PRO) regarding typical ailments in the real Life RCC population)

    Patient Reported Outcomes (PRO) regarding typical ailments in the real Life RCC population

    24 months

Secondary Outcomes (1)

  • Secondary Outcome Measures (Patient Reported Outcomes (PRO) regarding the impact of treatment on daily life)

    24 months

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patient with advanced (inoperable or metastatic) renal cell cancer at the start of the first line antitumoral therapy

You may qualify if:

  • Histologically confirmed renal cell carcinoma
  • Start of the first line systemic treatment
  • Ability to read and understand German
  • Written informed consent

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Multiple sites all over Germany

Multiple Locations, Germany

Location

MeSH Terms

Conditions

Carcinoma, Renal Cell

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsKidney NeoplasmsUrologic NeoplasmsUrogenital NeoplasmsNeoplasms by SiteFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesKidney DiseasesUrologic DiseasesMale Urogenital Diseases

Study Officials

  • Tilman Kirste, MD

    medical practise for oncology

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 26, 2015

First Posted

September 2, 2015

Study Start

August 19, 2015

Primary Completion

February 19, 2021

Study Completion

February 19, 2021

Last Updated

March 25, 2021

Record last verified: 2021-03

Data Sharing

IPD Sharing
Will not share

Locations

DE(1)